Zalicus discovers mechanism to treat multiple myeloma

“Combination drug regimens are quickly becoming the standard of care in the treatment of cancer and this is especially evident in multiple myeloma, where combination therapy has been shown to improve clinical outcomes for patients,” according to Dr. Mark H.N. Corrigan, president and CEO of Zalicus.